Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

641
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
641
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

765
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
765
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

718
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

1.1K
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1.1K
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

377
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
377
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

580
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial.

JACC. Heart failure·2026
Same author

Survival Outcomes in Middle-Aged and Older Patients With Advanced Heart Failure: A Propensity-Matched Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry.

JACC. Heart failure·2026
Same author

Microaxial flow pump before HeartMate 3: Should this bridge be built?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Association of tricuspid regurgitation with clinical events and quality of life after surgery for severe ischemic mitral regurgitation.

JTCVS structural and endovascular·2026
Same author

Cell-free mitochondrial DNA and microRNA-137 for early diagnosis of preeclampsia.

Frontiers in cardiovascular medicine·2026
Same author

Effect of sildenafil on platelet activation and mediators of vascular remodelling during LVAD support.

ESC heart failure·2026
Same journal

REVEALing New Standards: Low Risk Redefined.

JACC. Heart failure·2026
Same journal

Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial.

JACC. Heart failure·2026
Same journal

Sodium-Glucose Cotransporter 2 Inhibitor Following Left Ventricular Assist Device Implantation: A Randomized Controlled Trial.

JACC. Heart failure·2026
Same journal

Noninvasive Wearable-Based Algorithm to Predict Worsening Heart Failure by Change in Natriuretic Peptide Levels.

JACC. Heart failure·2026
Same journal

Long-Term HM3 Outcomes: Is Age the Signal or the Surrogate?

JACC. Heart failure·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies.

Jeffrey J Teuteberg1, Mark S Slaughter2, Joseph G Rogers3

  • 1University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

JACC. Heart Failure
|October 10, 2015
PubMed
Summary
This summary is machine-generated.

Optimizing anticoagulation, antiplatelet therapy, and blood pressure management is crucial for reducing cerebrovascular events in HeartWare ventricular assist device (HVAD) patients. Careful attention to these factors significantly impacts neurological event occurrence.

Keywords:
CVAVADcerebrovascular eventheart failurestrokeventricular assist device

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Related Experiment Videos

Last Updated: Apr 1, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Area of Science:

  • Cardiology
  • Neurology
  • Medical Devices

Background:

  • Left ventricular assist devices (LVADs) increase risk for both ischemic and hemorrhagic cerebrovascular events.
  • HeartWare ventricular assist device (HVAD) patients are susceptible to these neurological complications.

Purpose of the Study:

  • To identify risk factors for ischemic cerebrovascular accidents (ICVAs) and hemorrhagic cerebrovascular accidents (HCVAs) in HVAD patients.
  • To evaluate the impact of clinical parameters on cerebrovascular event prevalence post-HVAD implantation.

Main Methods:

  • Analysis of 382 patients from the ADVANCE trial and continued access protocol.
  • Multivariable modeling to assess risk factors for ICVAs and HCVAs.
  • Comparison of event rates before and after pump design modifications and antiplatelet therapy changes.

Main Results:

  • Overall prevalence of ICVA was 6.8% and HCVA was 8.4%.
  • Aspirin dosage and atrial fibrillation predicted ICVA; elevated mean arterial pressure, low-dose aspirin, and high INR predicted HCVA.
  • Improved blood pressure management protocols significantly reduced HCVA prevalence (1.8% vs. 10.8%).

Conclusions:

  • Anticoagulation, antiplatelet therapy, and blood pressure management are key modifiable factors influencing cerebrovascular events in HVAD recipients.
  • Implementing improved blood pressure management protocols can substantially decrease the incidence of hemorrhagic cerebrovascular accidents.
  • Clinical attention to these parameters is vital for mitigating serious neurological events in patients with HVAD support.